Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
CCRN vs TBI
Revenue, margins, valuation, and 5-year total return — side by side.
Staffing & Employment Services
CCRN vs TBI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Staffing & Employment Services |
| Market Cap | $326M | $182M |
| Revenue (TTM) | $1.05B | $1.25B |
| Net Income (TTM) | $-95M | $-53M |
| Gross Margin | 18.7% | 28.4% |
| Operating Margin | -0.3% | -2.6% |
| Forward P/E | 103.4x | — |
| Total Debt | $2M | $171M |
| Cash & Equiv. | $109M | $25M |
CCRN vs TBI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cross Country Healt… (CCRN) | 100 | 166.6 | +66.6% |
| TrueBlue, Inc. (TBI) | 100 | 39.1 | -60.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CCRN vs TBI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CCRN is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 0.78
- -28.1% 10Y total return vs TBI's -68.3%
- Lower volatility, beta 0.78, Low D/E 0.7%, current ratio 3.78x
TBI carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 3.1%, EPS growth 61.4%, 3Y rev CAGR -10.5%
- 3.1% revenue growth vs CCRN's -21.6%
- -4.3% margin vs CCRN's -9.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 3.1% revenue growth vs CCRN's -21.6% | |
| Quality / Margins | -4.3% margin vs CCRN's -9.0% | |
| Stability / Safety | Beta 0.78 vs TBI's 1.13, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +57.6% vs CCRN's -26.6% | |
| Efficiency (ROA) | -8.1% ROA vs CCRN's -17.9%, ROIC -5.2% vs -0.9% |
CCRN vs TBI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CCRN vs TBI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — CCRN and TBI each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TBI and CCRN operate at a comparable scale, with $1.2B and $1.1B in trailing revenue. Profitability is closely matched — net margins range from -4.3% (TBI) to -9.0% (CCRN). On growth, CCRN holds the edge at -23.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.1B | $1.2B |
| EBITDAEarnings before interest/tax | $13M | -$10M |
| Net IncomeAfter-tax profit | -$95M | -$53M |
| Free Cash FlowCash after capex | $42M | -$60M |
| Gross MarginGross profit ÷ Revenue | +18.7% | +28.4% |
| Operating MarginEBIT ÷ Revenue | -0.3% | -2.6% |
| Net MarginNet income ÷ Revenue | -9.0% | -4.3% |
| FCF MarginFCF ÷ Revenue | +4.0% | -4.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -23.6% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -20.3% | -37.5% |
Valuation Metrics
TBI leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
On an enterprise value basis, CCRN's 16.5x EV/EBITDA is more attractive than TBI's 159.8x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $326M | $182M |
| Enterprise ValueMkt cap + debt − cash | $220M | $328M |
| Trailing P/EPrice ÷ TTM EPS | -3.45x | -3.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 103.37x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 16.49x | 159.75x |
| Price / SalesMarket cap ÷ Revenue | 0.31x | 0.11x |
| Price / BookPrice ÷ Book value/share | 1.01x | 0.66x |
| Price / FCFMarket cap ÷ FCF | 6.76x | — |
Profitability & Efficiency
CCRN leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
TBI delivers a -18.7% return on equity — every $100 of shareholder capital generates $-19 in annual profit, vs $-24 for CCRN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to TBI's 0.62x. On the Piotroski fundamental quality scale (0–9), CCRN scores 6/9 vs TBI's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -24.3% | -18.7% |
| ROA (TTM)Return on assets | -17.9% | -8.1% |
| ROICReturn on invested capital | -0.9% | -5.2% |
| ROCEReturn on capital employed | -0.8% | -5.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.62x |
| Net DebtTotal debt minus cash | -$106M | $146M |
| Cash & Equiv.Liquid assets | $109M | $25M |
| Total DebtShort + long-term debt | $2M | $171M |
| Interest CoverageEBIT ÷ Interest expense | -1.56x | -46.19x |
Total Returns (Dividends Reinvested)
CCRN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CCRN five years ago would be worth $6,276 today (with dividends reinvested), compared to $2,175 for TBI. Over the past 12 months, TBI leads with a +57.6% total return vs CCRN's -26.6%. The 3-year compound annual growth rate (CAGR) favors CCRN at -24.5% vs TBI's -26.3% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +25.4% | +37.5% |
| 1-Year ReturnPast 12 months | -26.6% | +57.6% |
| 3-Year ReturnCumulative with dividends | -57.0% | -59.9% |
| 5-Year ReturnCumulative with dividends | -37.2% | -78.2% |
| 10-Year ReturnCumulative with dividends | -28.1% | -68.3% |
| CAGR (3Y)Annualised 3-year return | -24.5% | -26.3% |
Risk & Volatility
Evenly matched — CCRN and TBI each lead in 1 of 2 comparable metrics.
Risk & Volatility
CCRN is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than TBI's 1.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TBI currently trades 77.8% from its 52-week high vs CCRN's 67.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.78x | 1.13x |
| 52-Week HighHighest price in past year | $14.99 | $7.78 |
| 52-Week LowLowest price in past year | $7.43 | $3.18 |
| % of 52W HighCurrent price vs 52-week peak | +67.4% | +77.8% |
| RSI (14)Momentum oscillator 0–100 | 67.4 | 83.1 |
| Avg Volume (50D)Average daily shares traded | 451K | 382K |
Analyst Outlook
CCRN leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates CCRN as "Hold" and TBI as "Buy". Consensus price targets imply 4.9% upside for CCRN (target: $11) vs -5.0% for TBI (target: $6).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $10.61 | $5.75 |
| # AnalystsCovering analysts | 14 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.6% |
CCRN leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). TBI leads in 1 (Valuation Metrics). 2 tied.
CCRN vs TBI: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CCRN or TBI a better buy right now?
For growth investors, TrueBlue, Inc.
(TBI) is the stronger pick with 3. 1% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Analysts rate TrueBlue, Inc. (TBI) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CCRN or TBI?
Over the past 5 years, Cross Country Healthcare, Inc.
(CCRN) delivered a total return of -37. 2%, compared to -78. 2% for TrueBlue, Inc. (TBI). Over 10 years, the gap is even starker: CCRN returned -28. 1% versus TBI's -68. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CCRN or TBI?
By beta (market sensitivity over 5 years), Cross Country Healthcare, Inc.
(CCRN) is the lower-risk stock at 0. 78β versus TrueBlue, Inc. 's 1. 13β — meaning TBI is approximately 46% more volatile than CCRN relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 62% for TrueBlue, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CCRN or TBI?
By revenue growth (latest reported year), TrueBlue, Inc.
(TBI) is pulling ahead at 3. 1% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: TrueBlue, Inc. grew EPS 61. 4% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, TBI leads at -10. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CCRN or TBI?
TrueBlue, Inc.
(TBI) is the more profitable company, earning -3. 0% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps -3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCRN leads at -0. 3% versus -1. 7% for TBI. At the gross margin level — before operating expenses — TBI leads at 21. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CCRN or TBI more undervalued right now?
Analyst consensus price targets imply the most upside for CCRN: 4.
9% to $10. 61.
07Which pays a better dividend — CCRN or TBI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CCRN or TBI better for a retirement portfolio?
For long-horizon retirement investors, Cross Country Healthcare, Inc.
(CCRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78)). Both have compounded well over 10 years (CCRN: -28. 1%, TBI: -68. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CCRN and TBI?
These companies operate in different sectors (CCRN (Healthcare) and TBI (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.